# OnCo record nct05288166 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05288166/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05288166", "NCT05288166" ;
  schema:name "A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)"@en ;
  schema:alternateName "CYCLONE 3"@en ;
  schema:description "A phase 3 trial of Abemaciclib and Prednisone in prostate cancer, run by Eli Lilly and Company, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05288166/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05288166> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-04-14" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> .